指南与共识真菌感染

曲霉病的诊断与管理:2017年ESCMID-ECMM-ERS指南执行摘要

Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline.
指南 / 共识 · Clin Microbiol Infect · 2018-03-12

欧洲临床微生物学与感染病学会、欧洲医学真菌学联盟和欧洲呼吸学会联合指南聚焦曲霉病的诊断与管理。胸部CT及支气管镜肺泡灌洗在疑似侵袭性肺曲霉病患者中强烈推荐;血清和BAL半乳甘露聚糖推荐作为诊断标志物;艾沙康唑和伏立康唑是侵袭性肺曲霉病一线首选药物,脂质体两性霉素B中等支持;不推荐抗真菌药联合作为初始治疗。

要点

  • 疑似侵袭性肺曲霉病强烈推荐胸部CT和支气管镜肺泡灌洗。
  • 艾沙康唑和伏立康唑为侵袭性肺曲霉病一线首选,脂质体两性霉素B中等支持。
  • 不推荐抗真菌药物联合作为初始治疗。

核心结论

  • 艾沙康唑和伏立康唑是侵袭性肺曲霉病一线首选药物,脂质体两性霉素B获得中等支持。
  • 不推荐抗真菌药物联合作为初始治疗。
  • 泊沙康唑用于急性髓系白血病或骨髓增生异常综合征诱导化疗患者的一级预防获强烈推荐。

研究设计与样本

  • 欧洲临床微生物学与感染病学会、欧洲医学真菌学联盟和欧洲呼吸学会联合临床指南,聚焦曲霉病的诊断与管理。

主要发现

  • 疑似侵袭性肺曲霉病患者强烈推荐胸部CT及支气管镜肺泡灌洗。
  • 诊断强烈推荐直接镜检(优先使用光学增亮剂)、组织病理学和培养。
  • 推荐血清和BAL半乳甘露聚糖作为侵袭性曲霉病诊断标志物;PCR应考虑与其他诊断试验联合使用。
  • 所有临床相关曲霉分离株强烈推荐鉴定至物种复合体水平;当代监测项目发现耐药地区侵袭性疾病患者应进行抗真菌药敏试验。

关键数值与推荐

  • 艾沙康唑和伏立康唑为侵袭性肺曲霉病一线首选药物,脂质体两性霉素B获中等支持。
  • 不推荐抗真菌药物联合作为初始治疗。
  • 接受泊沙康唑混悬液或任何形式伏立康唑治疗侵袭性曲霉病的患者强烈推荐进行治疗药物监测。
  • 难治性疾病强烈推荐个体化方案,考虑逆转易感因素、更换药物类别和外科干预。
  • 急性髓系白血病或骨髓增生异常综合征接受诱导化疗患者强烈推荐泊沙康唑一级预防;高危患者强烈推荐二级预防。

临床怎么用

  • 疑似侵袭性肺曲霉病应行胸部CT和支气管镜肺泡灌洗。
  • 诊断采用直接镜检(优先光学增亮剂)、组织病理学和培养,并检测血清和BAL半乳甘露聚糖。
  • PCR应考虑与其他诊断试验联合使用。
  • 临床相关曲霉分离株应鉴定至物种复合体水平,耐药地区侵袭性疾病患者应行药敏试验。
  • 侵袭性肺曲霉病一线治疗选用艾沙康唑或伏立康唑,脂质体两性霉素B为中等支持选择。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The European Society for Clinical Microbiology and Infectious Diseases, the European Confederation of Medical Mycology and the European Respiratory Society Joint Clinical Guidelines focus on diagnosis and management of aspergillosis. Of the numerous recommendations, a few are summarized here. Chest computed tomography as well as bronchoscopy with bronchoalveolar lavage (BAL) in patients with suspicion of pulmonary invasive aspergillosis (IA) are strongly recommended. For diagnosis, direct microscopy, preferably using optical brighteners, histopathology and culture are strongly recommended. Serum and BAL galactomannan measures are recommended as markers for the diagnosis of IA. PCR should be considered in conjunction with other diagnostic tests. Pathogen identification to species complex level is strongly recommended for all clinically relevant Aspergillus isolates; antifungal susceptibility testing should be performed in patients with invasive disease in regions with resistance found in contemporary surveillance programmes. Isavuconazole and voriconazole are the preferred agents for first-line treatment of pulmonary IA, whereas liposomal amphotericin B is moderately supported. Combinations of antifungals as primary treatment options are not recommended. Therapeutic drug monitoring is strongly recommended for patients receiving posaconazole suspension or any form of voriconazole for IA treatment, and in refractory disease, where a personalized approach considering reversal of predisposing factors, switching drug class and surgical intervention is also strongly recommended. Primary prophylaxis with posaconazole is strongly recommended in patients with acute myelogenous leukaemia or myelodysplastic syndrome receiving induction chemotherapy. Secondary prophylaxis is strongly recommended in high-risk patients. We strongly recommend treatment duration based on clinical improvement, degree of immunosuppression and response on imaging.

来源:Clin Microbiol Infect,查看原文。版权归原作者所有。

引用

  1. Ullmann AJ, Aguado JM, Arikan-Akdagli S, et al. Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline. Clin Microbiol Infect. 2018. PMID: 29544767. doi:10.1016/j.cmi.2018.01.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。